(Q34181392)

English

LDL apheresis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

LDL apheresis (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Gilbert R Thompson

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

167

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1-13

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Plasma exchange in the management of homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Assessment of long-term plasma exchange for familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

LDL hemoperfusion--a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Particle release in extracorporeal low-density lipoprotein lowering therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Efficacy of different low-density lipoprotein apheresis methods

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

LDL-apheresis and concomitant ACE-inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Effect of nafamostat mesilate on bradykinin generation and hemodynamics during LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Lipoprotein(a) apheresis in severe coronary heart disease: an immunoadsorption method

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Blood antioxidants (vitamin E and beta-carotene) in long-term low density lipoprotein apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Preferential depletion of selenoprotein P in hypercholesterolaemic patients treated by LDL-apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Antioxidant status of hypercholesterolemic patients treated with LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Immunoadsorption and dextran sulfate cellulose LDL-apheresis for severe hypercholesterolemia: the Rogosin Institute experience 1982-1992

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Role of LDL apheresis in the management of hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concen

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Can aggressive lipid lowering using low-density lipoprotein apheresis prevent restenosis after percutaneous transluminal coronary angioplasty in patients with normocholesterolemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA?

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Ongoing clinical trials of lipid reduction therapy in patients with renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Therapeutic effects of LDL apheresis in the prevention of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Lipid apheresis: from a heroic treatment to routine clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Indications for low-density lipoprotein apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900251-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0021-9150(02)00251-4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34181392&oldid=1541618379"